Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

To assess the degree of subcutaneous and intraabdominal fat accumulation in growth hormone (GH) deficient adult men, and to evaluate the lipolytic effects of GH replacement therapy.

Who Took Part

According to the abstract, 46 men were involved.

The age groups tagged for this paper are adults, men only.

46 adult men (mean age 28.0 +/- 4.5 y) with childhood-onset GH deficiency (GHD).

Subcutaneous fat mass and fat distribution was assessed by measurement of skinfold thicknesses at seven different sites.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The men were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Neither the men nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

Intraabdominal fat mass was assessed by computerized tomography (CT).

Reference values were obtained from age- and sex-matched controls with a normal body mass index.

What Was Measured

Topics PubMed links to this paper include Adipose Tissue, Androgens, Anthropometry, Body Composition, Growth Disorders, Growth Hormone and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 46 men.

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1996 (International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.